News

Novozymes supplies Chinese pioneer
Enlarge image

BusinessSweden

Novozymes supplies Chinese pioneer

17.06.2012 - The Danish world market leader in enzyme technology, Novozymes A/S, will supply a large scale bioethanol production plant in China.

Baegsvaard – The deal was agreed during a visit from Hu Jintao, President of the People's Republic of China, in Copenhagen. Novozymes and its partner Shenqquan first announced the deal last month. China's Shengquan Group will start producing cellulosic ethanol in July, the company said.  According to Shenqquan, it will be the first in the world to do so on a commercial scale. The production will also be cost-competitive given that the feedstock, conventional ethanol, is a waste product from Shengquan's current production. The Chinese company is investing US $100m in the new groundbreaking facility. Novozymes will supply the enabling enzyme technology.

"When Shengquan opens its facility next month, it will be the first in the world," explains Steen Riisgaard, President and CEO of Novozymes. "It's fantastic to finally see this industry go commercial; for more than 10 years our researchers have worked to bring down the cost of producing ethanol from agricultural residues and household and industrial waste." Shengquan is a producer of furfural for resin production in the foundry industry. Furfural is produced from corncob xylose, with the cellulose from the corncob left behind as a waste product. Using Novozymes' enzymes, Shengquan will now be able to convert the cellulose into higher-value sugars that can be fermented to ethanol.  Shengquan will market the ethanol as an industrial solvent. "In order to continue to grow our country's economy at the same time as reducing our dependency on natural resources and minimizing the environmental impact, we need to start thinking of waste as an extremely valuable resource," comments Yi Lin Tang, President and Chairman of Shengquan Group. "Basically, we want and need to nurture a green and circular bioeconomy which is less dependent on fossil resources."

http://www.european-biotechnology-news.com/news/news/2012-02/novozymes-supplies-chinese-pioneer.html

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

M&AIrelandUK

05.08.2015 Irish pharma and biotech major Shire wants to be number one in orphan diseases, and is setting out to acquire US-American Baxalta in a US$30bn deal – by any means necessary.

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NORDIC NANOVECTOR (N)24.00 NOK23.71%
  • TRANSGENE (F)4.72 EUR23.56%
  • BAVARIAN NORDIC (D)41.03 EUR20.85%

FLOP

  • THROMBOGENICS (B)3.09 EUR-20.97%
  • ZELTIA (E)3.35 EUR-12.76%
  • OXFORD BIOMEDICA (UK)8.00 GBP-12.09%

TOP

  • KARO BIO (S)38.50 SEK2383.9%
  • TRANSGENE (F)4.72 EUR63.9%
  • BIOTECH PHARMACON (N)12.50 NOK33.7%

FLOP

  • THROMBOGENICS (B)3.09 EUR-42.4%
  • WILEX (D)2.05 EUR-41.4%
  • BIONOR PHARMA (N)1.26 NOK-39.4%

TOP

  • KARO BIO (S)38.50 SEK4595.1%
  • ADOCIA (F)87.65 EUR439.1%
  • GALAPAGOS (B)54.02 EUR324.7%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • BIOTEST (D)19.84 EUR-76.1%
  • NEOVACS (F)0.89 EUR-74.9%

No liability assumed, Date: 27.08.2015